Research shows that men who carry the BRCA1 and BRCA2 genes are at higher risk of developing prostate cancer than men without the genes.

A Swedish study finds that the combination of five genetic variations increases the risk of developing prostate cancer.

Researchers report that an experimental urine test can better distinguish between prostate cancer and benign conditions than both PSA and PCA3 testing.

In this new study, researchers examined data on testosterone levels in a total of 3,886 patients with prostate cancer and 6,438 healthy men. They found that men with the highest testosterone levels were just as likely to develop prostate cancer as men with the lowest. The same held true for concentrations of other sex hormones, including DHT, estradiol, and androstenedione.

Two teams of researchers suggest that focal therapy may be a promising treatment option for men with cancer confined to the prostate. However, more research is needed to determine its long-term effectiveness.

Physicians and researchers have long believed that consuming high amounts of calcium and dairy products increases the risk of prostate cancer, although study results have been inconsistent. Two recent studies make clear that the jury is still out.

Obese men tend to have lower PSA concentrations than men with healthier weights. As a result, fewer obese men undergo biopsies, potentially leaving prostate cancer undetected.

A study by Boston researchers found that hormone therapy may increase risk of death from heart disease, especially among patients who have had prostate surgery.

Studies reveal that lycopene, a nutrient found in tomatoes, does not seem to reduce prostate cancer risk.

A British study finds that repeat biopsies may play an important role in active surveillance for untreated, localized prostate cancer.

Anxiety, not clinical symptoms and disease progression, may sway patients toward treatment.

Blood and tissue levels of chromogranin A (CgA) may be early indication that prostate cancer that won’t respond for long to hormone therapy.

Study finds that finasteride may actually lower the overall risk of prostate cancer and aid in the detection of aggressive tumors. An earlier study had implicated finasteride in the development of these deadlier tumors.

To explore the link between multivitamins and prostate cancer, scientists at the National Cancer Institute studied 295,344 men who participated in the National Institutes of Health–AARP Diet and Health Study.

Researchers have identified several genetic variations that raise prostate cancer risk, variations that may also account for the higher incidence of prostate cancer in African Americans.

Researchers at Johns Hopkins University School of Medicine have developed a new blood test for prostate cancer, which in a preliminary study proved better than the PSA test at identifying which men have cancer. The new test measures levels of the protein EPCA-2, which — unlike PSA — is produced almost exclusively by cancerous tissue.